Affordable Access

deepdyve-link
Publisher Website

An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer

Authors
  • KISS, DAVID1, 2
  • MACHACKOVA, TANA3
  • SOUCKOVA, KAMILA3
  • FABIAN, PAVEL4
  • KREPELKOVA, IVETA5
  • SVOBODA, MAREK1
  • KISS, IGOR1, 3
  • 1 Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
  • 2 o, Czech Republic
  • 3 Central European Institute of Technology, Masaryk University, Brno, Czech Republic
  • 4 Department of Clinical and Experimental Pahology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
  • 5 BioVendor Laboratorni Medicína a.s., Brno, Czech Republic
Type
Published Article
Journal
In Vivo
Publisher
International Institute of Anticancer Research
Publication Date
Sep 03, 2021
Volume
35
Issue
5
Pages
2809–2814
Identifiers
DOI: 10.21873/invivo.12567
PMID: 34410972
PMCID: PMC8408711
Source
PubMed Central
Keywords
Disciplines
  • Research Article
License
Unknown

Abstract

Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b-3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival (p=0.024). Conclusion: We have successfully confirmed miR-92b-3p to be up-regulated in tumor tissue of mCRC patients with good response to bevacizumab/FOLFOX therapy.

Report this publication

Statistics

Seen <100 times